MX2024004850A - Metodos y usos de bag3 para el tratamiento de la inflamacion. - Google Patents
Metodos y usos de bag3 para el tratamiento de la inflamacion.Info
- Publication number
- MX2024004850A MX2024004850A MX2024004850A MX2024004850A MX2024004850A MX 2024004850 A MX2024004850 A MX 2024004850A MX 2024004850 A MX2024004850 A MX 2024004850A MX 2024004850 A MX2024004850 A MX 2024004850A MX 2024004850 A MX2024004850 A MX 2024004850A
- Authority
- MX
- Mexico
- Prior art keywords
- bag3
- found
- proteins
- extrinsic
- apoptosis
- Prior art date
Links
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 title abstract 2
- 101000697871 Homo sapiens BAG family molecular chaperone regulator 3 Proteins 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 108700028369 Alleles Proteins 0.000 abstract 1
- 102000004091 Caspase-8 Human genes 0.000 abstract 1
- 108090000538 Caspase-8 Proteins 0.000 abstract 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract 1
- 241000699660 Mus musculus Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010026552 Proteome Proteins 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000006624 extrinsic pathway Effects 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000006623 intrinsic pathway Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000001700 mitochondrial membrane Anatomy 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 238000011830 transgenic mouse model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Environmental Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Bag3 es una proteína multifuncional que se expresa predominantemente en el corazón, el músculo esquelético, el sistema nervioso central y en muchos tipos de cáncer. Aunque BAG3 se clonó hace sólo una década, los estudios han demostrado que las variantes genéticas, en particular las que dan lugar a la haploinsuficiencia, pueden conducir a una disfunción ventricular izquierda grave; sin embargo, los mecanismos responsables completos todavía no son claros. Para obviar la influencia de la propia insuficiencia cardíaca en la biología de Bag3, se estudiaron ratones transgénicos portadores de un único alelo inactivado entre las 8 y 10 semanas de edad, antes de que se evidenciaran signos evidentes de insuficiencia cardíaca. Los resultados fueron sorprendentes e informativos. En primer lugar, se encontró que a pesar de un fenotipo normal, los jóvenes Bag3+/- tenían cambios marcados en el proteoma que se caracterizaban por cambios en proteínas asociadas con el metabolismo y la apoptosis. De forma consistente con este hallazgo, se observó una disminución de los niveles de proteínas críticas encargadas de mantener el potencial de membrana mitocondrial. También se encontró que los ratones jóvenes cambiaban de un equilibrio entre las vías extrínseca e intrínseca de la apoptosis. Sin embargo, en presencia de estrés y en ausencia de Bag3 se produjo un cambio de un sistema dominante equilibrado a un sistema dominante extrínseco (caspasa 8 escindida). El conjunto diverso de vías críticas reguladas por Bag3 sugiere una función más importante, especialmente durante el estrés, y que esta función podría incluir servir como un pegamento intracelular que retiene las proteínas donde pueden ser más efectivas en lugar de que se encuentren accidentalmente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163262953P | 2021-10-22 | 2021-10-22 | |
| US202263368765P | 2022-07-18 | 2022-07-18 | |
| PCT/US2022/047479 WO2023069744A1 (en) | 2021-10-22 | 2022-10-21 | Bag3 methods and uses for treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004850A true MX2024004850A (es) | 2024-09-19 |
Family
ID=86059617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004850A MX2024004850A (es) | 2021-10-22 | 2022-10-21 | Metodos y usos de bag3 para el tratamiento de la inflamacion. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230241162A1 (es) |
| EP (1) | EP4419127A1 (es) |
| JP (1) | JP2024540887A (es) |
| KR (1) | KR20240130680A (es) |
| AU (1) | AU2022370875A1 (es) |
| CA (1) | CA3235431A1 (es) |
| CL (1) | CL2024001238A1 (es) |
| IL (1) | IL312509A (es) |
| MX (1) | MX2024004850A (es) |
| WO (1) | WO2023069744A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250010008A (ko) * | 2022-05-03 | 2025-01-20 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 뇌에서 bag3 및 단백질 품질 관리 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1323733A1 (en) * | 2001-12-28 | 2003-07-02 | Arturo Leone | BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases |
-
2022
- 2022-10-21 JP JP2024523137A patent/JP2024540887A/ja active Pending
- 2022-10-21 CA CA3235431A patent/CA3235431A1/en active Pending
- 2022-10-21 WO PCT/US2022/047479 patent/WO2023069744A1/en active Application Filing
- 2022-10-21 EP EP22884544.2A patent/EP4419127A1/en active Pending
- 2022-10-21 US US17/971,477 patent/US20230241162A1/en active Pending
- 2022-10-21 IL IL312509A patent/IL312509A/en unknown
- 2022-10-21 KR KR1020247016733A patent/KR20240130680A/ko active Pending
- 2022-10-21 MX MX2024004850A patent/MX2024004850A/es unknown
- 2022-10-21 AU AU2022370875A patent/AU2022370875A1/en active Pending
-
2024
- 2024-04-19 CL CL2024001238A patent/CL2024001238A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3235431A1 (en) | 2023-04-27 |
| KR20240130680A (ko) | 2024-08-29 |
| CL2024001238A1 (es) | 2025-01-31 |
| IL312509A (en) | 2024-07-01 |
| WO2023069744A1 (en) | 2023-04-27 |
| AU2022370875A1 (en) | 2024-05-23 |
| EP4419127A1 (en) | 2024-08-28 |
| JP2024540887A (ja) | 2024-11-06 |
| US20230241162A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001238A1 (es) | Métodos y usos de bag3 para el tratamiento de la inflamación | |
| Dalle-Donne et al. | The actin cytoskeleton response to oxidants: from small heat shock protein phosphorylation to changes in the redox state of actin itself | |
| Wallace | Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine | |
| Mitchell et al. | ATP production in Chlamydomonas reinhardtii flagella by glycolytic enzymes | |
| Föller et al. | Chorein‐sensitive polymerization of cortical actin and suicidal cell death in chorea‐acanthocytosis | |
| Sasaki et al. | DNA polymerase γ inhibition by vitamin K3 induces mitochondria‐mediated cytotoxicity in human cancer cells | |
| ES2179945T3 (es) | Compuestos de tetralina con actividad de resistencia a multiples farmacos. | |
| Deponte et al. | Glutathione S‐transferase from malarial parasites: structural and functional aspects | |
| Pacheu-Grau et al. | Mitochondrial dysfunction and its role in tissue-specific cellular stress | |
| Casas-Martinez et al. | Redox regulation of UPR signalling and mitochondrial ER contact sites | |
| BR9811697A (pt) | Indução de esterilidade masculina em plantas por expressão de altos nìveis de avidina | |
| Malhan et al. | Circadian regulation in aging: Implications for spaceflight and life on earth | |
| Pathak et al. | Complex I and energy thresholds in the brain | |
| Campo et al. | Mitochondria in the aging muscles of flies and mice: new perspectives for old characters | |
| AR014674A1 (es) | Secuencia de nucleotidos aislada para regular la muerte celular y aumentar la resistencia a enfermedades, a patogenos de plantas, gen quimerico, vector detransformacion, planta transformada, semillas, metodo para aumentar la resistencia a enfermedad de un patogeno en una planta, metodo para producir | |
| Azevedo et al. | Disrupted glutamate signaling in Drosophila generates locomotor rhythms in constant light | |
| AR046953A1 (es) | Variantes de genes que codifican para proteinas de la via de metabolismo de productos quimicos puros | |
| Lee et al. | Negative regulation of the novel norpAP24 suppressor, diehard4, in the endo-lysosomal trafficking underlies photoreceptor cell degeneration | |
| Lo Vasco et al. | Neuropeptide Y reduces the expression of PLCB2, PLCD1 and selected PLC genes in cultured human endothelial cells | |
| Pellegrino-Coppola | Regulation of the mitochondrial permeability transition pore and its effects on aging | |
| Wakimoto et al. | Na+/Ca2+ exchanger-deficient mice have disorganized myofibrils and swollen mitochondria in cardiomyocytes | |
| Glass et al. | Is rapamycin a rapalog? | |
| Ramachandran et al. | Exploiting metabolic and antioxidant pathways to maintain vision in blinding disease | |
| Lu et al. | STRIPAK regulation of katanin microtubule severing in the Caenorhabditis elegans embryo | |
| Singh et al. | Gαi3 signaling is associated with sexual dimorphic expression of the clock-controlled output gene Dbp in murine liver |